CH655656B
(fi)
*
|
1982-10-07 |
1986-05-15 |
|
|
CA1225594A
(en)
*
|
1983-05-20 |
1987-08-18 |
Jourge Heller |
Method for percutaneously administering physiologically active agents
|
DE3406497A1
(de)
*
|
1984-02-23 |
1985-09-05 |
Mueller Bernhard Willi Werner |
Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung
|
WO1985003878A1
(en)
*
|
1984-03-01 |
1985-09-12 |
Sandoz Ag |
Pharmaceutical compositions
|
US5364628A
(en)
*
|
1985-05-31 |
1994-11-15 |
Sandoz Ltd. |
Pharmaceutical compositions
|
US5639724A
(en)
*
|
1984-07-24 |
1997-06-17 |
Sandoz Ltd. |
Cyclosporin galenic forms
|
JPS61280426A
(ja)
*
|
1985-06-04 |
1986-12-11 |
Ikeda Mohandou:Kk |
消炎鎮痛用貼付剤
|
US4767625A
(en)
*
|
1985-09-02 |
1988-08-30 |
Kao Corporation |
Lamella type single phase liquid crystal composition and oil-base cosmetic compositions using the same
|
US4690774A
(en)
|
1985-09-11 |
1987-09-01 |
Chesebrough Pond's Inc. |
Novel translucent water in oil emulsions
|
US4797272A
(en)
|
1985-11-15 |
1989-01-10 |
Eli Lilly And Company |
Water-in-oil microemulsions for cosmetic uses
|
DE3805744C2
(de)
*
|
1987-03-04 |
1999-09-23 |
Novartis Ag |
Phenylcarbamate zur Hemmung der Acetylcholinesterase
|
IL88076A
(en)
*
|
1987-10-28 |
1993-01-14 |
Nippon Shinyaku Co Ltd |
Fat emulsions as drug carriers
|
KR0148748B1
(ko)
*
|
1988-09-16 |
1998-08-17 |
장 크라메르, 한스 루돌프 하우스 |
사이클로스포린을 함유하는 약학조성물
|
US5342625A
(en)
*
|
1988-09-16 |
1994-08-30 |
Sandoz Ltd. |
Pharmaceutical compositions comprising cyclosporins
|
US6007840A
(en)
*
|
1988-09-16 |
1999-12-28 |
Novartis Ag |
Pharmaceutical compositions comprising cyclosporins
|
US5332577A
(en)
*
|
1988-12-27 |
1994-07-26 |
Dermamed |
Transdermal administration to humans and animals
|
US5241925A
(en)
*
|
1988-12-27 |
1993-09-07 |
Dermamed |
Apparatus and techniques for administering veterinary medicaments
|
US7081445B2
(en)
|
1989-02-20 |
2006-07-25 |
Novartis Ag |
Cyclosporin galenic forms
|
DE3908047A1
(de)
*
|
1989-03-13 |
1990-09-20 |
Desitin Arzneimittel Gmbh |
Hochdisperse pharmazeutische zusammensetzung
|
US5324521A
(en)
*
|
1989-12-18 |
1994-06-28 |
Dermamed |
Systems for transdermal administration of medicaments
|
US5149719A
(en)
*
|
1990-04-27 |
1992-09-22 |
Minnesota Mining And Manufacturing Company |
Composition for transdermal penetration of medicaments
|
FR2673537B1
(fr)
*
|
1991-03-08 |
1993-06-11 |
Oreal |
Utilisation d'agents de penetration hydrophiles dans les compositions dermatologiques pour le traitement des onychomycoses, et compositions correspondantes.
|
US5688761A
(en)
*
|
1991-04-19 |
1997-11-18 |
Lds Technologies, Inc. |
Convertible microemulsion formulations
|
DE69229779T2
(de)
*
|
1991-04-19 |
1999-12-23 |
Lds Technologies, Inc. |
Konvertierbare mikroemulsionsverbindungen
|
HU223343B1
(hu)
*
|
1991-05-20 |
2004-06-28 |
Novartis Ag. |
Allil-amin-származékot tartalmazó gyógyászati készítmények és eljárás azok előállítására
|
US6005001A
(en)
*
|
1991-05-20 |
1999-12-21 |
Novartis Ag (Formerly Sandoz Ag) |
Pharmaceutical composition
|
GB9111611D0
(en)
*
|
1991-05-30 |
1991-07-24 |
Sandoz Ltd |
Liposomes
|
US6262022B1
(en)
|
1992-06-25 |
2001-07-17 |
Novartis Ag |
Pharmaceutical compositions containing cyclosporin as the active agent
|
GB9126209D0
(en)
*
|
1991-12-10 |
1992-02-12 |
Orion Yhtymae Oy |
Drug formulations for parenteral use
|
WO1993011798A1
(en)
*
|
1991-12-16 |
1993-06-24 |
Alza Corporation |
Improved formulations with hydrophobic permeation enhancers
|
US5629019A
(en)
*
|
1992-02-27 |
1997-05-13 |
Alza Corporation |
Formulations with hydrophobic permeation enhancers
|
WO1993023010A1
(en)
|
1992-05-13 |
1993-11-25 |
Sandoz Ltd. |
Ophthalmic compositions containing a cyclosporin
|
ES2168271T3
(es)
|
1992-09-25 |
2002-06-16 |
Novartis Ag |
Composiciones farmaceuticas que contienen ciclosporinas.
|
JPH08505367A
(ja)
*
|
1992-10-16 |
1996-06-11 |
スミスクライン・ビーチャム・コーポレイション |
医薬用エマルジョン組成物
|
WO1994019000A1
(en)
*
|
1993-02-17 |
1994-09-01 |
Smithkline Beecham Corporation |
Microemulsions containing pharmaceutical compositions
|
EP0789580B1
(de)
|
1994-11-03 |
2002-06-05 |
Novartis AG |
Neue zubereitungsformen des cyclosporins zur oralen applikation mit einfacher zusammensetzung und hoher bioverfügbarkeit und verfahren zu deren herstellung
|
DE4442999A1
(de)
|
1994-12-02 |
1996-06-05 |
Hexal Pharma Gmbh |
Pharmazeutische Zusammensetzung mit einem aktiven Loratidin-Metaboliten
|
DE19544507B4
(de)
|
1995-11-29 |
2007-11-15 |
Novartis Ag |
Cyclosporin enthaltende Präparate
|
US5958876A
(en)
*
|
1996-06-19 |
1999-09-28 |
Novartis Ag |
Cyclosporin-containing pharmaceutical compositions
|
ES2229473T3
(es)
|
1997-01-30 |
2005-04-16 |
Novartis Ag |
Composiciones farmaceuticas sin aceite que contienen ciclosporina a.
|
US6187747B1
(en)
|
1997-09-08 |
2001-02-13 |
Panacea Biotech Limited |
Pharmaceutical composition comprising cyclosporin
|
IN188719B
(fi)
*
|
1997-09-08 |
2002-11-02 |
Panacea Biotec Ltd |
|
US6346511B1
(en)
|
1997-09-08 |
2002-02-12 |
Panacea Biotec Limited |
Pharmaceutical composition comprising cyclosporin
|
US6008191A
(en)
*
|
1997-09-08 |
1999-12-28 |
Panacea Biotec Limited |
Pharmaceutical compositions containing cyclosporin
|
UY25225A1
(es)
|
1997-10-29 |
2000-12-29 |
Smithkline Beecham Plc |
Derivados de pleuromutilina utiles como agentes antimicrobianos
|
US6391282B1
(en)
*
|
1997-11-10 |
2002-05-21 |
Flemington Pharmaceutical Corp. |
Antihistamine sprays and ointments for relief of delayed contact dermatitis
|
DE19825856A1
(de)
*
|
1998-06-10 |
1999-12-16 |
Labtec Gmbh |
Topische Arzneimittelzubereitung
|
PL348193A1
(en)
|
1998-12-11 |
2002-05-06 |
Pharmasolutions |
Self-emulsifying compositions for drugs poorly soluble in water
|
US7374779B2
(en)
*
|
1999-02-26 |
2008-05-20 |
Lipocine, Inc. |
Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
|
US6294192B1
(en)
*
|
1999-02-26 |
2001-09-25 |
Lipocine, Inc. |
Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
|
US7732404B2
(en)
|
1999-12-30 |
2010-06-08 |
Dexcel Ltd |
Pro-nanodispersion for the delivery of cyclosporin
|
CA2529528A1
(en)
*
|
2003-06-20 |
2004-12-29 |
Ronald Aung-Din |
Topical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
|
US7112561B2
(en)
|
2003-12-08 |
2006-09-26 |
Bentley Pharmaceuticals, Inc. |
Pharmaceutical compositions and methods for insulin treatment
|
US7740875B2
(en)
|
2004-10-08 |
2010-06-22 |
Mediquest Therapeutics, Inc. |
Organo-gel formulations for therapeutic applications
|
US20060078580A1
(en)
|
2004-10-08 |
2006-04-13 |
Mediquest Therapeutics, Inc. |
Organo-gel formulations for therapeutic applications
|
US9308203B2
(en)
*
|
2008-10-01 |
2016-04-12 |
Taiwan Biotech Co., Ltd. |
Pressure sensitive adhesive matrix device or system for the treatment or prevention of onychomycosis or tinea pedis
|
US11304960B2
(en)
|
2009-01-08 |
2022-04-19 |
Chandrashekar Giliyar |
Steroidal compositions
|
US9034858B2
(en)
|
2010-11-30 |
2015-05-19 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US9358241B2
(en)
|
2010-11-30 |
2016-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US20180153904A1
(en)
|
2010-11-30 |
2018-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US20120148675A1
(en)
|
2010-12-10 |
2012-06-14 |
Basawaraj Chickmath |
Testosterone undecanoate compositions
|
WO2016033556A1
(en)
|
2014-08-28 |
2016-03-03 |
Lipocine Inc. |
BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
|
WO2016033549A2
(en)
|
2014-08-28 |
2016-03-03 |
Lipocine Inc. |
(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
|
US10328087B2
(en)
|
2015-07-23 |
2019-06-25 |
Therapeuticsmd, Inc. |
Formulations for solubilizing hormones
|
WO2017173071A1
(en)
|
2016-04-01 |
2017-10-05 |
Therapeuticsmd, Inc. |
Steroid hormone pharmaceutical composition
|
US10286077B2
(en)
|
2016-04-01 |
2019-05-14 |
Therapeuticsmd, Inc. |
Steroid hormone compositions in medium chain oils
|
JP2020503269A
(ja)
|
2016-11-28 |
2020-01-30 |
リポカイン インコーポレーテッド |
経口ウンデカン酸テストステロン療法
|